Taysha Gene Therapies, Inc. (TSHA)
TSHA Stock Price Chart
Explore Taysha Gene Therapies, Inc. interactive price chart. Choose custom timeframes to analyze TSHA price movements and trends.
TSHA Company Profile
Discover essential business fundamentals and corporate details for Taysha Gene Therapies, Inc. (TSHA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Sept 2020
Employees
73.00
Website
https://www.tayshagtx.comCEO
Sean P. Nolan
Description
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
TSHA Financial Timeline
Browse a chronological timeline of Taysha Gene Therapies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 May 2026
Upcoming earnings on 24 Feb 2026
Upcoming earnings on 12 Nov 2025
EPS estimate is -$0.09, while revenue estimate is $1.51M.
Earnings released on 12 Aug 2025
EPS came in at -$0.09 falling short of the estimated -$0.07 by -28.57%, while revenue for the quarter reached $1.99M , beating expectations by +14.88%.
Earnings released on 15 May 2025
EPS came in at -$0.08 matching the estimated -$0.08, while revenue for the quarter reached $2.30M , beating expectations by +112.31%.
Earnings released on 26 Feb 2025
EPS came in at -$0.07 surpassing the estimated -$0.08 by +12.50%, while revenue for the quarter reached $2.02M , missing expectations by -1.51%.
Earnings released on 13 Nov 2024
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%, while revenue for the quarter reached $1.79M , missing expectations by -12.90%.
Earnings released on 12 Aug 2024
EPS came in at -$0.09 surpassing the estimated -$0.10 by +10.00%, while revenue for the quarter reached $1.11M , missing expectations by -58.20%.
Earnings released on 14 May 2024
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%, while revenue for the quarter reached $3.41M , beating expectations by +33.24%.
Earnings released on 19 Mar 2024
EPS came in at $0.35 surpassing the estimated -$0.09 by +488.89%, while revenue for the quarter reached $3.60M , beating expectations by +36.00%.
Earnings released on 14 Nov 2023
EPS came in at -$0.13 matching the estimated -$0.13, while revenue for the quarter reached $4.75M , beating expectations by +79.09%.
Earnings released on 14 Aug 2023
EPS came in at -$0.38 falling short of the estimated -$0.31 by -22.58%, while revenue for the quarter reached $2.40M , beating expectations by +128.10%.
Earnings released on 11 May 2023
EPS came in at -$0.28 surpassing the estimated -$0.35 by +20.00%, while revenue for the quarter reached $4.71M , beating expectations by +6.62K%.
Earnings released on 28 Mar 2023
EPS came in at -$0.99 falling short of the estimated -$0.41 by -141.46%, while revenue for the quarter reached $2.50M , missing expectations by -69.41%.
Earnings released on 8 Nov 2022
EPS came in at -$0.64 surpassing the estimated -$0.89 by +28.09%.
Earnings released on 11 Aug 2022
EPS came in at -$0.84 surpassing the estimated -$1.05 by +20.00%.
Earnings released on 16 May 2022
EPS came in at -$1.31 falling short of the estimated -$1.04 by -25.96%.
Earnings released on 31 Mar 2022
EPS came in at -$1.32 falling short of the estimated -$1.21 by -9.09%.
Earnings released on 10 Nov 2021
EPS came in at -$1.35 falling short of the estimated -$1.02 by -32.35%.
Earnings released on 16 Aug 2021
EPS came in at -$1.09 falling short of the estimated -$0.81 by -34.57%.
Earnings released on 11 May 2021
EPS came in at -$0.87 falling short of the estimated -$0.54 by -61.11%.
Earnings released on 3 Mar 2021
EPS came in at -$1.04 falling short of the estimated -$0.37 by -181.08%.
Earnings released on 12 Nov 2020
EPS came in at -$1.28 falling short of the estimated -$0.17 by -652.94%.
Earnings released on 25 Sept 2020
EPS came in at -$0.09 .
TSHA Stock Performance
Access detailed TSHA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.